Safety and immunogenicity of a quadrivalent influenza vaccine in adults 65 y of age and older
作者： David P. Greenberg , Corwin A. Robertson , H. Keipp Talbot , Michael D. Decker
DOI: 10.1080/21645515.2017.1344375
关键词:
摘要: ABSTRACTFrequent mismatches between the predominant circulating B strain lineage and in trivalent influenza vaccines have resulted missed opportunities to prevent illness. Quadrivalent containing strains from each of 2 lineages been developed for improved prevention infections. Here, we describe results a phase III, randomized, double-blind, active-controlled, multicenter trial examining safety immunogenicity split-virion inactivated quadrivalent vaccine (IIV4) 675 adults ≥ 65 y age (NCT01218646). Participants were randomly assigned 1:1:1 receive single intramuscular injection with investigational IIV4, or one (IIV3s): licensed IIV3 Victoria-lineage an Yamagata-lineage strain. Post-vaccination (day 21) hemagglutinin inhibition titers all induced by IIV4...
sci-hub.se 参考文章(18)
Rebecca Cox, Correlates of protection to influenza virus, where do we go from here? Human Vaccines & Immunotherapeutics. ,vol. 9, pp. 405- 408 ,(2013) , 10.4161/HV.22908
Sharon E. Frey, Mari Rose Aplasca-De Los Reyes, Humberto Reynales, Nancy Nazaire Bermal, Uwe Nicolay, Vas Narasimhan, Eduardo Forleo-Neto, Ashwani Kumar Arora, Comparison of the safety and immunogenicity of an MF59®-adjuvanted with a non-adjuvanted seasonal influenza vaccine in elderly subjects. Vaccine. ,vol. 32, pp. 5027- 5034 ,(2014) , 10.1016/J.VACCINE.2014.07.013
Stéphanie Pépin, Yves Donazzolo, Alen Jambrecina, Camille Salamand, Melanie Saville, Safety and immunogenicity of a quadrivalent inactivated influenza vaccine in adults. Vaccine. ,vol. 31, pp. 5572- 5578 ,(2013) , 10.1016/J.VACCINE.2013.08.069
Josefina B Cadorna-Carlos, Terry Nolan, Charissa Fay Borja-Tabora, Jaime Santos, M Cecilia Montalban, Ferdinandus J de Looze, Peter Eizenberg, Stephen Hall, Martin Dupuy, Yanee Hutagalung, Stéphanie Pépin, Melanie Saville, None, Safety, immunogenicity, and lot-to-lot consistency of a quadrivalent inactivated influenza vaccine in children, adolescents, and adults: A randomized, controlled, phase III trial. Vaccine. ,vol. 33, pp. 2485- 2492 ,(2015) , 10.1016/J.VACCINE.2015.03.065
Bruce Y. Lee, Sarah M. Bartsch, Alyssa M. Willig, The economic value of a quadrivalent versus trivalent influenza vaccine. Vaccine. ,vol. 30, pp. 7443- 7446 ,(2012) , 10.1016/J.VACCINE.2012.10.025
Robert B. Belshe, The need for quadrivalent vaccine against seasonal influenza. Vaccine. ,vol. 28, ,(2010) , 10.1016/J.VACCINE.2010.08.028
David P. Greenberg, Corwin A. Robertson, Michael J. Noss, Mark M. Blatter, Rex Biedenbender, Michael D. Decker, Safety and immunogenicity of a quadrivalent inactivated influenza vaccine compared to licensed trivalent inactivated influenza vaccines in adults. Vaccine. ,vol. 31, pp. 770- 776 ,(2013) , 10.1016/J.VACCINE.2012.11.074
William W Thompson, David K Shay, Eric Weintraub, Lynnette Brammer, Carolyn B Bridges, Nancy J Cox, Keiji Fukuda, Influenza-Associated Hospitalizations in the United States JAMA. ,vol. 292, pp. 1333- 1340 ,(2004) , 10.1001/JAMA.292.11.1333
Kamran Haq, Janet E McElhaney, Immunosenescence: influenza vaccination and the elderly Current Opinion in Immunology. ,vol. 29, pp. 38- 42 ,(2014) , 10.1016/J.COI.2014.03.008
Carrie Reed, Martin I. Meltzer, Lyn Finelli, Anthony Fiore, Public health impact of including two lineages of influenza B in a quadrivalent seasonal influenza vaccine. Vaccine. ,vol. 30, pp. 1993- 1998 ,(2012) , 10.1016/J.VACCINE.2011.12.098